In three independent cohorts of patients with PD or parkinsonism on levodopa plus a decarboxylase inhibitor, elevated levels of dopa decarboxylase (L-aromatic amino acid decarboxylase) enzyme activity were present in 82% of patients in this population (van Rumund et al. 2021). Here, DDC is linked to Parkinson disease.